Gain Therapeutics (GANX) vs Tenax Therapeutics (TENX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Gain Therapeutics (GANX) has outperformed Tenax Therapeutics (TENX) over the past year, losing 22.0% versus a loss of 74.5%. Over five years, GANX leads with a -76.7% price change compared with -99.9% for TENX. Gain Therapeutics is the larger company by market cap ($70.5 million vs $69.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GANX | TENX |
|---|---|---|
| Share price | $1.62 | $1.86 |
| Market cap | $70.48M | $69.61M |
| 1-day change | -3.29% | -2.62% |
| YTD return | -49.84% | -84.33% |
| 1-year return | -21.98% | -74.50% |
| 5-year return | -76.73% | -99.93% |
| EPS (TTM) | $-0.50 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.34 | $19.40 |
| 52-week low | $1.53 | $1.31 |
| Distance from 52-week high | -62.79% | -90.41% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +345.82% | +575.27% |
| Average volume | 493.98K | 5.46M |
| Shares outstanding | 43.64M | 37.42M |
| Employees | 20 | 14 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GANX has outperformed TENX by 52.5 percentage points over the past year.
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Healthcare · Biotechnology · 20 employees
About Tenax Therapeutics
TENX stock →Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Healthcare · Biotechnology · 14 employees
GANX vs TENX FAQ
Which is bigger, Gain Therapeutics or Tenax Therapeutics?
Gain Therapeutics (GANX) is larger, with a market capitalization of $70.48M compared with $69.61M for Tenax Therapeutics (TENX).
Which stock has performed better over the past year, GANX or TENX?
GANX returned -21.98% over the past 12 months, compared with -74.50% for TENX (price return, excluding dividends). Past performance does not predict future results.
Are Gain Therapeutics and Tenax Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.